EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The metabolism of floctafenin in man and rodents


Journal of Clinical Pharmacology 19(1): 20-30
The metabolism of floctafenin in man and rodents
Floctafenin (FFn), 2,3-dihydroxypropyl--N--(8--trifluoromethyl--4--quinolyl) anthranilate, a new nonnarcotic analgesic drug, was studied in man, mice, and the isolated perfused rat liver. In all species the drug is rapidly hydrolyzed to floctafenic acid (FFa). In seven volunteer subjects who each received a single oral dose of 400 mg floctafenin on an empty stomach, the blood concentration of FFa usually reached a maximum between 1 and 2 hours (mean 1.57 +/- 1.28 microgram/ml at 1.5 hours) and declined over the next 6 hours. Eight hours after drug administration the mean concentration of FFa in the blood of the volunteers was 0.1 +/- .05 microgram/ml. Approximately 25 per cent of the administered dose of floctafenin was recovered as FFa and hydroxy-FFa in the urine collected from each subject for 48 hours after drug administration. In mice each having received a single intraperitoneal dose of floctafenin (2 mg), the concentration of floctafenin declined by about 50 per cent in 15 minutes, and this decline was accompanied by a rise in the concentration of FFa that remained constant for 3 hours. The analgesic effect observed after administration of floctafenin to humans is likely to be mediated by its major metabolite, FFa. In these volunteers no free floctafenin was detected in the blood.

(PDF same-day service: $19.90)

Accession: 006717566

PMID: 33200

DOI: 10.1002/j.1552-4604.1979.tb01613.x



Related references

Metabolism of a new analgesic agent 2 3 di hydroxypropyl n 8 trifluoromethyl 4 quinolyl anthranilate ru 15750 floctafenin in man. Federation Proceedings 35(3): 565, 1976

Floctafenin in stomatology. Lille Medical 23(5 Suppl 1): 387-389, 1978

Floctafenin in dysmenorrhea a multicenter trial. Jornal Brasileiro de Ginecologia 98(1-2): 75-80, 1988

Granulomatous interstitial nephritis after floctafenin. Clinical Nephrology 22(4): 213-214, 1984

Identification of a floctafenin metabolite in a urinary calculus. Annales de Biologie Clinique 45(5): 546-550, 1987

Clinical trial of a new analgesic, floctafenin in 100 patients. Lille Medical 21 Suppl 4: 920-925, 1976

Pharmacokinetic study of a peripheral analgesic, floctafenin, in man, mouse, rat, and dog. Drug Metabolism and Disposition: the Biological Fate of Chemicals 3(3): 133-147, 1975

Renal function and histologic studies in rats treated by floctafenin. Pathologie-Biologie 26(9-10): 581-586, 1978

The clinical investigation of a new non-narcotic analgesic agent: floctafenin (Idarac). Current Therapeutic Research, Clinical and Experimental 18(2): 303-314, 1975

Minimal metabolism summit metabolism and plasma thyroxine in rodents from different environments. Comparative Biochemistry & Physiology A 81(3): 687-694, 1985